搜尋結果
2010年12月21日 · Eisai submitted an application to the Japanese Ministry of Health, Labour and Welfare on April 28, 2010 seeking approval of additional twice-daily dosage and administration of Pariet® in order to broaden the range of treatment options available to patients with refractory reflux esophagitis.
2015年2月24日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced that it will launch proton pump inhibitor Pariet® Tablets 5 mg (rabeprazole sodium) in Japan on February 26. The new 5 mg Tablet was approved by the Ministry of Health, Labour, and Welfare on December 26, 2014 and listed on the National Health Insurance ...
2018年8月17日 · TOKYO August 17, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck & Co., Inc., Kenilworth N.J., U.S.A., known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA ® (lenvatinib mesylate) for the first-line ...
2017年4月3日 · Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that the smell identification test “UPSIT Series” will be launched today for sale to health insurance pharmacies and local governments in Japan. The UPSIT Series was developed by Sensonics International (Headquarters: New Jersey, USA; CEO: Richard ...
2022年1月19日 · FIRST SUBJECT ENROLLED IN PHASE II/III STUDY OF EISAI’S ANTI-MTBR TAU ANTIBODY E2814 FOR DOMINANTLY INHERITED ALZHEIMER'S DISEASE (DIAD), CONDUCTED BY DIAN-TU. EISAI’S ANTI-AMYLOID BETA PROTOFIBRIL ANTIBODY LECANEMAB SELECTED AS THE BACKGROUND THERAPY FOR THE TAU NEXGEN STUDY. For Print （186KB）. January 19, 2022.
2023年1月7日 · Using the recently published data from the large global confirmatory Phase 3 clinical trial, Clarity AD, Eisai will work quickly to file a Supplemental Biologics License Application (sBLA) to the FDA for approval under the traditional pathway. INDICATION.
Welcome to the Eisai Official Corporate Website Eisai Co., Ltd. Page.
